|Bid||14.70 x 400000|
|Ask||14.80 x 400000|
|Day's Range||14.64 - 14.80|
|52 Week Range||10.35 - 22.70|
|PE Ratio (TTM)||92.50|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.58|
Evotec AG announced today that its multi-target alliance with Bayer has advanced another promising small molecule into Phase I for the treatment of endometriosis, a painful, debilitating reproductive condition that affects approximately 176 million women worldwide.
Evotec AG announced today a strategic collaboration with Petra Pharma Corporation . Through the collaboration, Petra will access Evotec's INDiGO platform to accelerate the development of its lead programme Petra-01, which is being developed for a range of oncological indications, through to the submission of an Investigational New Drug Application with the U.S.
Evotec AG (XTRA:EVT), a life sciences company based in Germany, saw a significant share price rise of over 20% in the past couple of months on the XTRA. With manyRead More...
Evotec AG has launched its accelerated drug development service INDiGO . With the launch of INDiGO , Evotec's expertise and capabilities are uniquely combined under one roof to deliver better drug candidates to patients faster and more efficiently than standard industry approaches.
Evotec AG’s (XTRA:EVT) most recent return on equity was a substandard 8.96% relative to its industry performance of 9.32% over the past year. EVT’s results could indicate a relatively inefficientRead More...
Evotec AG and Sanofi have entered into exclusive negotiations for Evotec to accelerate infectious disease research and development through a new open innovation platform near Lyon, France.
Evotec AG announced today that its management will be presenting at the 24th Prior Kapitalmarktkonferenz, Frankfurt, Germany, and at the H.C.
Evotec AG and MaRS Innovation announced today that they have identified the first project to be developed under their LAB150 partnership.
Evotec AG and APEIRON Biologics AG, a company focused on cancer immunotherapy, announced today that the companies received the first milestone payment from Sanofi under a 3-party alliance signed in August 2015.
Evotec AG announced today that its management will be presenting at the 17th German Corporate Conference 2018 jointly hosted by UniCredit and Kepler Cheuvreux, Frankfurt, Germany, and will be attending the 36th Annual J.P.
Evotec AG / Key word : Miscellaneous EVOTEC'S ACADEMIC BRIDGE LAB282 WITH OXFORD UNIVERSITY CELEBRATING ONE YEAR OF IMPACT
Evotec AG / Key word : Miscellaneous EVOTEC RECEIVES CLINICAL MILESTONE AS PART OF ITS DISCOVERY ALLIANCE WITH BOEHRINGER INGELHEIM
Evotec AG announced today that its management will be presenting at the Jefferies 2017 London Healthcare Conference in London, UK, at the German Equity Forum in Frankfurt, Germany, and at the Annual Berenberg European Conference in Surrey, UK, and will be attending DZ BANK Equity Conference in Frankfurt, Germany, and dbAccess Pharmaceutical and Healthcare Corporate Day in London, UK.
Evotec AG announced today that its strategic alliance with Celgene has reached a first milestone triggering revenues of $ 5.0 m to Evotec, which are recognised in the third quarter of 2017.
Evotec AG and Exscientia Ltd today announced that Evotec has made a EUR 15 m investment to take a minority stake in Exscientia.
Evotec AG and MaRS Innovation today announced the launch of "LAB150". This transformational Toronto-based partnership will give Canadian academic institutions and teaching hospitals access to the world-class infrastructure and drug discovery expertise of Evotec and pair it with cutting-edge drug discovery projects emerging from the 15 member institutions of MaRS Innovation.
Evotec AG and the European Investment Bank announced today that the EIB has granted Evotec an unsecured loan facility of up to EUR 75 m to support Evotec's Innovate strategy.
Evotec AG and ABIVAX today announced a strategic collaboration to discover and develop novel treatments for multiple serious viral infectious diseases.
Evotec AG announced today that its management will be presenting at the Morgan Stanley 15th Annual Global Healthcare Conference in New York, USA; 6th German Corporate Conference, Berenberg/Goldman Sachs in Munich, Germany, and Baader Investment Conference, Munich, Germany, and will be attending Goldman Sachs' 7th Annual Biotech Symposium in London, UK, and Bank of America Merrill Lynch Global Healthcare ...
Evotec AG today announced that, effective mid-August 2017, it has successfully completed the acquisition of Aptuit as announced in detail on 30 July 2017.